You Position: Home > Paper
Effect of lenalidomide combined with interferon and interleukin-2 for treatment of refractory/relapsed or minimal residual disease-positive acute myelogenous leukemia
( views:150, downloads:158 )
- Author:
- No author available
- Journal Title:
- Journal of Leukemia & Lymphoma
- Issue:
- 12
- DOI:
- 10.3760/cma.j.issn.1009-9921.2019.12.010
- Key Word:
- 白血病,髓样,急性;复发;难治;微小残留病;干扰素类;白细胞介素2;来那度胺
Abstract： 目的 探讨来那度胺联合干扰素(IFN)、白细胞介素2(IL-2)治疗难治复发或微小残留病(MRD)阳性急性髓系白血病(AML)患者的效果及安全性.方法 选择2013年8月至2019年5月在郑州大学附属肿瘤医院住院的既往接受过沙利度胺联合IFN、IL-2治疗的再经来那度胺联合IFN和IL-2治疗的12例AML患者.法、美、英(FAB)协作组分型:M01例,M11例,M2a 4例,M2b 3例,M4EO 1例,M5b 2例;伴FLT3-ITD突变阳性2例,伴c-kit突变阳性1例;低危组2例,中危组7例,高危组3例.难治AML 3例,复发AML 7例(复发1次者3例,复发2次者4例;近期复发者5例,远期复发者2例),MRD阳性2例.评估12例患者疗效及不良反应.结果 12例患者均接受了>1个周期的来那度胺联合IFN、IL-2治疗,其中,4例达形态学完全缓解(CR),2例达CR伴血细胞不完全恢复(CRi),4例未缓解,1例MRD较前下降,1例MRD较前升高;总有效(CR+CRi+部分缓解+MRD下降)7例.观察期间未出现皮疹、便秘、心动过缓、周围神经不良反应等,6例患者出现Ⅲ级及以上骨髓抑制.治疗过程中无因并发症死亡的患者,所有患者缓解持续时间2～20个月.结论 来那度胺联合IFN、IL-2治疗难治复发或MRD阳性AML有效,可使MRD阳性患者的MRD值下降,可成为AML的一种新的治疗手段.
- [1]魏冲,姜志超,王昊天,等.来那度胺可抑制单核细胞向M2型巨噬细胞分化及相关细胞因子的分泌[J].2015,(6).
- [2]米瑞华,陈琳,魏旭东,等.干扰素α-1b、白细胞介素2联合沙利度胺方案干预治疗微小残留病阳性急性髓系白血病的疗效分析[J].2019,(2).
- [3]魏旭东,艾昊,米瑞华,等.沙利度胺联合干扰素、白细胞介素-2治疗复发难治性急性髓系白血病[J].2016,(11).
- [4]Griffiths, Elizabeth A.,Brady, William E.,Tan, Wei,etc.A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia[J].2016,43.
- [5]E.N. McSweeney,C.P. Worman,C.P. Tsakona,etc.Low-Dose Recombinant Alfa-2a-lnterferon: A Feasible Maintenance Therapy in Acute Myeloid Leukaemia in the Older Patient[J].1993,89(1).
- [6]N O, Hill,A, Pardue,A, Khan,etc.Clinical trials of human leukocyte interferon in malignancy.[J].1900,41.
- [7]Luo, Jing,Gagne, Joshua J.,Landon, Joan,etc.Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study[J].2017,70.
- [8]Lori Brightman,Marie-France Demierre.Thalidomide in mycosis fungoides[J].2005,52(6).
- [9]Skarbnik, Alan P.,Goy, Andre H..Lenalidomide for mantle cell lymphoma[J].2015,8(3).
- [10]Dominique Maraninchi,Norbert Vey,Patrice Viens,etc.A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia[J].1998,31(3-4).
- [11]Langston A,Flowers CR,Winton E,etc.Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.[J].2007,13(1).
- [12]Chawla-Sarkar M.,Lindner D. J.,Liu Y.-F.,etc.Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis[J].2003,8(3).
- [13]Hitoshi, Yoshiji,Ryuichi, Noguchi,Shigeki, Kuriyama,etc.Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice.[J].2005,13(3).
- [14]Ruan, Jia,Martin, Peter,Christos, Paul,etc.Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma[J].2018,132(19).
- [15]张之南, 沈悌主编.血液病诊断及疗效标准[M].2007.
- [16]Blum W,Klisovic RB,Becker H,etc.Dose escalation of lenalidomide in relapsed or refractory acute leukemias.[J].2010,28(33).
- [17]S, Giralt,S, O'Brien,M, Talpaz,etc.Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.[J].1995,1(2).